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Abstract: Indicated for treating hyperlipidemias
and for the prevention of cardiovascular disease
(CVD), statins rank among the most commonly pre-
scribed drug classes. While statins are considered to
be highly effective in preventing atherosclerotic
events, a substantial portion of treated patients still
progress to overt CVD. Genetic factors are thought
to contribute substantially to treatment outcome.
Several candidate genes have been associated with
statin dose requirements and treatment outcomes,
but a clinically relevant pharmacogenomics test to
guide statin therapy has not yet emerged. Here we
define basic pharmacogenomics terminology, pres-
ent strong candidate genes (CETP, HMGCR,
SLCO1B1, ABCB1, and CYP3A4/5), and discuss the
challenges in developing much-needed statin phar-
macogenomics biomarkers for predicting treatment
outcomes. [Discovery Medicine 16(86):45-51, August 2013]
Cardiovascular Disease and Statins
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in the United States. More than
one in three Americans have some form of CVD, and
coronary artery disease (CAD) alone accounts for one
in every six deaths and treatment costs exceed 300 bil-
lion dollars annually (Gaziano et al., 2010). Thus, CVD
is one of the most pervasive and expensive disorders
facing our nation. The relatively high efficacy and low
side effect profile of statins drove them to become the
gold standard in preventing adverse cardiac events
associated with hyperlipidemia. Large clinical trials
have shown that statins reduce the risk of major vascu-
lar events in a linear fashion with a 20% risk reduction
for every 1 mmol/L decrease in low-density-lipoprotein
(LDL) cholesterol (Amarenco and Labreuche, 2009).
Twenty-five years after receiving FDA approval, statins
remain a cornerstone of the U.S. healthcare system with
simvastatin being the third most prescribed drug (IMS
Health, 2012). However, responses to statin therapy can
be influenced by various factors and are not universal:
some patients cannot attain their lipid-reduction goals,
some experience atherosclerotic events despite therapy,
and some suffer adverse events such as hepatitis or
myopathy. This article offers a brief introduction to
pharmacogenomics testing, describes a variety of genes
that influence statin pharmacology, and characterizes
current and future trends in statin pharmacogenomics
research. As readers become increasingly familiar with
pharmacogenomics research and terminology, the level
of detail is increased with each subsequent gene pre-
sented in this review. Readers will note also that differ-
ences regarding genetic influence exist among statin
types and can be attributed to dissimilarities in their
chemical structure, potency, and disposition.
Pharmacogenomics
Pharmacogenomics is the study of how genetic factors
influence inter-individual variability of drug response.
Many patients, clinicians, and scientists may not be
entirely familiar with its background and the terminol-
ogy used in the pharmacogenomic literature. A brief
review of the commonly-used terminology follows. The
coding sequence of DNA base pairs for a particular
gene is the genotype, and a phenotype refers to a trait
resulting from the protein product encoded by a gene.
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Examples of phenotypes include blood type, hair color,
and the extent to which an individual metabolizes or
responds to a certain pharmacotherapy. A gene’s name
is italicized and often refers to its protein product (e.g.,
the CYP3A5 gene encodes for the CYP3A5 enzyme).
The genotype is formed from two alleles per autosomal
gene, one maternal and one paternal. Homozygotes
possess two of the same alleles, and heterozygotes pos-
sess two different alleles. The most common allele in a
population is referred to as the wild-type, and allele fre-
quencies often vary from one patient population to the
next. Most sequence variations are single nucleotide
polymorphisms (SNPs, pronounced “snips”). A SNP is
a single DNA base pair substitution that may result in a
different gene product. SNPs can be classified as struc-
tural RNA polymorphisms (srSNPs), regulatory poly-
morphisms (rSNPs), or polymorphisms in coding
regions (cSNPs): srSNPs alter mRNA processing and
translation, rSNPs alter transcription, and cSNPs alter
protein sequence and function. A haplotype is a combi-
nation of alleles or set of SNPs at nearby locations on a
chromosome that are inherited together. Tag SNP(s) do
not necessarily alter the function of a gene or its protein
product. They are representative SNPs associated with
other polymorphism(s), known or unknown, which are
responsible for functional change(s). Recently, genetic
associations with a phenotype have been done on a
large scale, with millions of SNPs measured in thou-
sands of subjects. This approach, called a genome-wide
association study or GWAS, has revealed countless can-
didate genes for clinical traits, but only a few have
resulted in a practical clinical application. SNPs may by
themselves exert a pharmacokinetic effect (i.e., how the
body processes the drug), a pharmacodynamic effect
(i.e., how the drug affects the body), or both. Often they
may act in concert with other genes or other genetic fac-
tors (e.g., promoter or enhancer regions).
Pharmacodynamic effects can result from a pharmaco-
kinetic effect or can result from variations in a pharma-
cologic target (e.g., HMG CoA reductase is the target
enzyme of statins). Establishing a genotype-phenotype
association can involve clinical studies, animal trans-
genic studies, or molecular and cellular functional
assays. A comprehensive approach to pharmacogenom-
ic investigation should include examining the influence
of genes involved in drug absorption, transport, metab-
olism, excretion, and proteins related to mechanism of
action. Following this approach, we describe a variety
of genes that influence various aspects of statin pharma-
cology.
Cholesterol Ester Transferase Protein (CETP)
CETP is involved in cholesterol metabolism by trans-
porting cholesteryl esters into the liver and functions to
exchange triglycerides from LDL to high-density-
lipoprotein (HDL) cholesterol. Variants in CETP have
been associated with differences in cholesterol levels,
cardiovascular outcomes, and response to statin phar-
macotherapy. Early studies found carriers of the Taq 1B
polymorphism in CETP to have lower CETP concentra-
tions, higher HDL concentrations, and lower risk of
progression of coronary artery disease compared with
noncarriers (Freeman et al., 1994; Kuivenhoven et al.,
1998; Willer et al., 2008). Unexpectedly, statin-treated
male carriers had a higher 10-year mortality rate com-
pared with noncarriers of the Taq 1B variant (Regieli et
al., 2008). These findings suggest that statin treatment
may be more beneficial in noncarriers even though
untreated carriers have a lower risk of CAD progression
than untreated noncarriers. The association between the
Taq 1B SNP and HDL-cholesterol levels and the risk of
CAD was substantiated in a large meta-analysis
(n=13,677), but the interaction between the polymor-
phism and statin therapy was not (Boekholdt et al.,
2005). Arguably, the Taq 1B polymorphism is now
regarded as a tag SNP because in vitro studies have
failed to provide a mechanistic or functional explana-
tion regarding its association with differences in choles-
terol levels, cardiovascular risk, and response to statins.
Recently, two regulatory variants have been identified
in CETP, a SNP in exon 9 enhancing the formation of a
non-functional or dominant-negative splice isoform,
and SNPs in the promoter and enhancer regions affect-
ing transcription. Both are significantly associated with
cholesterol levels and sex-dependent cardiovascular
risk (Papp et al., 2012). Their associations with
response to statin therapy are currently being investi-
gated in several patient cohorts. Further investigation of
CETP is likely to provide the insight necessary for
developing a clinical test capable of identifying individ-
uals not likely to benefit from statin therapy.
HMG CoA Reductase (HMGCR)
As the rate-limiting step of cholesterol synthesis, the
HMGCR enzyme is the primary target of statins. By
inhibiting HMGCR activity, statin therapy results in
decreased intrahepatic cholesterol synthesis.
Subsequently, bloodstream-to-liver cholesterol trans-
port is increased, and the resulting reduction of choles-
terol concentrations in the bloodstream slows the pro-
gression of atherosclerosis. Genetic variation of
HMGCR, however, can result in significantly attenuat-
ed responses to statin pharmacotherapy. One of about
ten described haplotypes of HMGCR, haplotype 7 (H7)
is defined by the following three SNPs: rs17244841,
rs3846662, and rs17238540 (Krauss et al., 2008). The
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rs# is a unique identification number for genetic poly-
morphisms recorded in the Single Nucleotide
Polymorphism Database (dbSNP). The dbSNP is main-
tained by the National Center for Biotechnology
Information (NCBI) in collaboration with the National
Human Genome Research Institute (NHGRI). The
genetic variation associated with H7 affects alternative
splicing of the HMGCR mRNA, resulting in decreased
sensitivity to statins. In the Pravastatin
Inflammation/CRP Evaluation (PRINCE) trial,
Cholesterol and Pharmacogenomics (CAP) study, and
the Genetics of Diabetes Audit and Research in Tayside
Scotland (GoDARTS) database, carriers of the H7 hap-
lotype had a diminished response to statins: Reductions
in LDL cholesterol were about 20% less and the likeli-
hood of achieving predefined cholesterol goals was
about 50% less than that of noncarriers of H7 (Chasman
et al., 2004; Donnelly et al., 2008; Krauss et al., 2008).
These findings, however, were not replicated in the
Atorvastatin Comparative Cholesterol Efficacy and
Safety Study (ACCESS), Assessment of Lescol in
Renal Transplantation (ALERT), Prospective Study of
Pravastatin in the Elderly at Risk (PROPSER), or
Treatment to New Targets (TNT) studies (Thompson et
al., 2005; Singer et al., 2007; Polisecki et al., 2008;
Thompson et al., 2009). Variation of response to statin
therapy is better explained by HMGCR haplotypes than
by genotypes, but the available evidence is insufficient
at present to warrant routine testing.
Self-limited, dose-dependent statin-induced muscle
toxicity is the most commonly recognized serious
adverse outcome associated with statin therapy.
Recently, another type of myopathy has been linked to
statin use: Immune-mediated necrotizing myopathy
(IMNM) is characterized by anti-HMGCR autoantibod-
ies (Mammen et al., 2011). The amount of autoantibody
is associated with increased creatine kinase (CK) levels
and muscle weakness for statin-exposed patients, but
not for statin-naive patients afflicted with IMNM.
Furthermore, immunotherapy reversed muscle weak-
ness and decreased the levels of CK and autoantibodies
only for statin-exposed IMNM patients (Werner et al.,
2012). As IMNM is a statin-related autoimmune
myopathy involving HMCGR, genetic variations in
HMGCR and genes involved in immunity should be
investigated for phenotype-genotype associations
regarding the incidence and severity of IMNM.
Solute Carrier Organic Anion Transporter Family,
Member 1B1 (SLCO1B1)
As illustrated in Figure 1, SLCO1B1 transports statins
and metabolites from the blood stream into the cells of
the liver. The primary lipid-lowering action of statins,
competitive inhibition of the cholesterol-synthesizing
enzyme HMGCR, occurs within hepatocytes. A loss-of-
function (LOF) or a decrease-of-function (DOF) variant
in SLCO1B1 should arguably result in lower efficacy.
Significant reductions in efficacy, however, have not
been shown to be associated with variants of SLCO1B1
(Peters et al., 2010; Yang et al., 2010). Variant
SLCO1B1 alleles have demonstrated significant phar-
macokinetic influence. The area under the curve of the
time-concentration curve (AUC) was approximately
double (n=41, p<0.01) for SLCO1B1 variant allele car-
riers compared to homozygous carriers of the wild-type
allele (Niemi et al., 2004). Homozygous carriers in the
Go-DARTS database were approximately three times
more likely (n=4,340, p<0.01) to be statin intolerant,
with an increase in serum creatine kinase concentration
to above the upper limit of normal or an increase in
serum alanine aminotransferase concentration to above
1.5 times the upper limit of normal (Donnelly et al.,
2010). A GWAS investigation in patients taking simvas-
tatin 80 mg daily found that heterozygous and homozy-
gous SLCO1B1 variant allele carriers were 4.5 and 16.9
times more likely to have developed myopathy com-
pared to homozygous carriers of the wild-type allele
(n=175, p<0.01 after correction for multiple-hypotheses
testing). The odds ratios (OR) were 2.6 and 5.2 for het-
erozygous and homozygous carriers, respectively, for
individuals taking only 40 mg daily (Link et al., 2008).
In a case-control study (n=108) the association was
replicated for individuals taking simvastatin (OR: 3.2,
p<0.05) but not for those taking atorvastatin (OR: 4.5,
p=0.48) (Brunham et al., 2012). Although the associa-
tion between the SLCO1B1 variant and simvastatin-
related muscle toxicity is robust, the adverse outcome
can still occur in the absence of the variant allele. Other
potentially deleterious variants in SLCO1B1 or in other
genes may increase systemic exposure of statins,
increasing risk of developing muscle-toxicity risk.
ATP-binding Cassette, Sub-family B1 (ABCB1)
As depicted in Figure 1, statins and their metabolites
are eliminated via bile and urine. ABCB1 transports
statins and metabolites from hepatocytes to bile and
from renal cells to urine. The following three SNPs
have demonstrated significant direct influence on statin
pharmacokinetics and indirect influence on statin phar-
macodynamics: rs1128503, rs2032582, and rs1045642.
These polymorphisms are also denoted as c.1236C>T,
c.2677G>T/A, and c.3435C>T of ABCB1, referring to
the DNA base substitution and their position in the
gene’s cDNA sequence. For example, c.1236C>T indi-
cates that the polymorphism has a thymine in place of a
cytosine at base position 1236 of the ABCB1 cDNA
48
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sequence. SNP C3435T alone has also been associated
with decreased ABCB1 mRNA stability, leading to
reduced expression of ABCB1 (Wang et al., 2005). In
combination with SNP 1236 or 2677 or both, SNP 3435
affects codon usage dynamics and timing of cotransla-
tional folding, resulting in alterations in the transporters
structure and function. Individuals with the 3-locus
genotype pattern (T;T)-(T;T)-(T;T), also referred to as
the TTT haplotype, had an AUC that was 60% larger
for simvastatin’s metabolite (p=0.039) and 55% larger
for atorvastatin’s metabolite (p<0.025) compared to
those with the CGT haplotype (Keskitalo et al., 2008).
Genotyping for ABCB1 is not routinely performed;
however, investigations that combine ABCB1 with
other influential statin-pharmacokinetic genes
(SLCO1B1, CYP3A) aim to develop clinically-relevant
tests to aid in statin-dose selection and avoid toxicity.
Cytochrome P450, Family 3, Subfamily A (CYP3A)
CYP3A enzymes are involved in the metabolism of
nearly half of the most-commonly prescribed medica-
tions. Of the statins, they metabolize atorvastatin,
lovastatin, and simvastatin. CYP3A4 is the most promi-
nent member of CYP3A, and a DOF allele,
CYP3A4*22, has recently been characterized. The
allele nomenclature for CYP enzymes designates sig-
nificant SNPs with a number preceded by an * (pro-
nounced “star”). This designation suggests that suffi-
cient evidence exists regarding the functionality, preva-
lence, and clinical relevance of the polymorphism
(Sim, 2013). The *1 designation is typically assigned to
the wild-type or “normal functioning” allele, and a
polymorphism can be referred to by rs# or by “star”
designation. CYP3A4 enzyme level and activity were
greater in wild-type homozygous patients than in
CYP3A4*22 allele carriers, and carriers of the DOF
allele required only 20-60% (n=235, p<0.05) of the
statin dose required by homozygotic wild-type patients
taking stable doses of atorvastatin, simvastatin, or
lovastatin for optimal lipid control (Wang et al., 2011).
The steady-state serum concentrations of simvastatin
and its active acid metabolite were about 50% higher
(n=~800, p<0.05) in CYP3A4*22 allele carriers com-
pared to wild-type homozygous patients (Kitzmiller
J.P., unpublished data). Significant associations
between the *22 allele and increased lipid-lowering
response to simvastatin have been reported (Elens et
al., 2011), and CYP3A4*22 allele carriers may be at a
higher risk (n=~300, p=~0.06) for developing statin-
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Figure 1. Statin pharmacokinetics and pharmacodynamics. FA, fatty acid; HDL, high-density lipoprotein; IDL, interme-
diate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein. Adapted from pathway dia-
grams under copyright by PharmGKB; with permission from PharmGKB and Stanford University. 
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induced myopathy (Kitzmiller J.P., unpublished data).
About 7% of Caucasians possess at least one
CYP3A4*22 allele, and the frequency of the DOF allele
has not yet been well characterized in non-Caucasian
patient populations.
Although in vitro studies strongly suggest that
CYP3A5 plays only a limited role in statin metabolism
(Park et al., 2008), some investigators have reported
significant associations among CYP3A5 and statin
pharmacokinetics and pharmacodynamics. The
CYP3A5*1 allele is the only allele that produces high
levels of full-length CYP3A5 mRNA and functional
protein. Approximately a dozen other CYP3A5 alleles
have been described, with CYP3A5*3 being the most
common LOF allele. Simvastatin exposure was higher
for CYP3A5*3 homozygotes compared with CYP3A5*
1 homozygotes (Kim et al., 2007), and diminished
lipid-lowering responses have been reported for
CYP3A5 *1 homozygotes (Kivistö et al., 2004; Shin et
al., 2011). Conversely, other findings suggest that
CYP3A5 status does not influence statin pharmacoki-
netics and pharmacodynamics: Systemic exposure of
the biologically-active atorvastatin acid metabolite was
not significantly associated with CYP3A5 status
(Willrich et al., 2008), and no significant association
was observed between CYP3A5*3 and efficacy or tol-
erability of simvastatin (Fiegenbaum et al., 2005). As
shown in Figure 1, other enzymes including CYP2C
and Uridine’5 Diphospho-Glucuronosyl Transferase
(UGT) are involved in the metabolism of certain
statins; however, genetic variation regarding those
enzymes seems to be of lesser consequence regarding
statin pharmacology and has not been as aggressively
investigated.
Current and Future Trends 
Retrospective, prospective, case-study, cross-sectional,
candidate-gene, and genome-wide approaches have
been implemented in a variety of patient populations
across the United States and around the world in order
to investigate the impact of genetic polymorphisms on
statin pharmacotherapy. In addition to the select genes
presented in this review several other key genes (APOE
LDL-R, PCSK9, KIF6, and CLMN) have significant
influence on statin pharmacology, and analyses inte-
grating several key genes and their interactions have
been reported. A clinically-relevant pharmacogenomic
test regarding statins, however, has not yet emerged.
Alone no gene has a large enough clinical impact to
warrant routine testing. A multi-gene approach involv-
ing the integration of a large patient population, howev-
er, may eventually provide useful guidance regarding
statin pharmacotherapy, similar to that provided for
warfarin at warfarindosing.org. The pharmacogenomic
data provided at this site provides guidance for war-
farin dosing based on clinical factors, concomitant
medications, comorbidities, and genetic status of
VKORC1, CYP2C9, CYP4F2, and GGCX. The popu-
larity of this site among clinicians and patients has
increased, and FDA-approved drug labeling of war-
farin recommends considering a patient’s CYP2C9 and
VKORC1 status when choosing an initial dose (Bristol-
Myers Squibb, 2010). As statin-related genetic research
advances, a similar multi-gene approach also encom-
passing clinical factors may be established to assist cli-
nicians in answering the following fundamental ques-
tions: How likely is my patient to benefit from taking a
statin? Which statin is best for my patient? What dose
should be chosen initially? Does my patient’s individ-
ual risk for adverse events outweigh their expected
benefit? Should my patient be monitored more fre-
quently for adverse events?
Examining current clinical trials involving statins and
pharmacogenomics provides some foresight, and
ClinicalTrials.gov is a registry and results database of
publicly- and privately-supported clinical studies con-
ducted around the world. Registration of trials involv-
ing pharmaceutics is mandated or at least strongly rec-
ommended by the following governing organizations:
U.S. Food and Drug Administration, the World Health
Organization, National Institutes of Health, the World
Medical Association, and the International Committee
of Medical Journal Editors (U.S. National Library of
Medicine, 2013). Approximately 1,500 currently-regis-
tered trials involve a statin, and 20 of them list a pri-
mary genetic component. A random sampling of the
remaining registered statin trials suggests that about
10% include genetic factors as a secondary study meas-
urement. The most studied statin is atorvastatin with
576 registered trials, followed by simvastatin, rosuvas-
tatin, pravastatin, fluvastatin, lovastatin, pitavastatin,
and cerivastatin with the following numbers of respec-
tive registered clinical trials: 422, 282, 128, 58, 53, 49,
and 1. Of the registered statin trials 16, 20, 30, and 34%
are phase 1, 2, 3, and 4 trials, respectively; 35, 4, 17,
and 44% list their funding source as Industry, Federal,
Combination, and Other, respectively (U.S. National
Library of Medicine, 2013).
Many large genotype-phenotype datasets regarding
statin pharmacotherapy exist, and more are developing.
Combining these data would provide advantages
toward accomplishing the primary goal of statin phar-
macogenomics research: development of clinically-
meaningful pharmacogenomic tests to guide statin
pharmacotherapy. A major challenge in combining
these data involves differences in predefined and limit-
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ed phenotypic domains. A GWAS approach typically
determines associations between the variation of mil-
lions of SNPs and a few predefined phenotypes. A
newly-developed alternative method, a phenome-wide
association study (PheWAS) approach, utilizes all avail-
able phenotypic information and all genetic variants in
the estimation of associations between genotypes and
phenotypes (Pendergrass, Brown‐Gentry et al., 2011).
This approach provides an expanded view of the rela-
tionship between genetic variation and networks of phe-
notypes because a diverse range of phenotypes can be
combined and investigated. Flexible and adaptive statis-
tical methods like the PheWAS approach are likely to
significantly advance the development of pharmacoge-
nomic applications, but prospective randomized trials
evaluating improvement in patient outcomes are likely
to remain the gold standard for determining the clinical
significance of a pharmacogenomics test.
Arguably, the majority of statin clinical trials and phar-
macogenomics research focus on statin efficacy related
to lipid-lowering. However, the overall benefits of statin
therapy seem to go beyond those expected from changes
in lipid levels alone. Recent studies indicate that some
of the pleiotropic effects (i.e., effects other than the
drug’s initial indication) of statins include increasing
the availability of endogenous nitric oxide, enhancing
plaque stability, improving endothelial function, and
decreasing inflammation. Statin’s pleiotropic effects are
likely to be genetically-influenced, and future statin
pharmacogenomics research and clinical investigations
should investigate potential genotype-phenotype associ-
ations.
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